Operating cash flow swung from -$11.6M in 2025Q4 to $35.2M in 2026Q3, with the cash-to-net-income ratio fluctuating sharply, suggesting cash conversion depends heavily on working capital timing.
Eton Pharmaceuticals, Inc. (ETON) cash flow statement — 9-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 |
|---|
| Cash from Operations | 38.35M | 10.52M | 969K | 6.82M | 4.82M | -4.72M | -22.35M | -18.03M | -8.14M | -4.72M |
| Operating CF Margin % | - | 13.16% | 2.48% | 21.54% | 22.69% | -21.62% | -57297.44% | -1879.67% | - | - |
| Operating CF Growth % | -971.43% | 986.07% | -85.78% | 41.36% | 202.12% | 78.87% | -23.97% | -121.31% | -72.64% | - |
| Net Income | 49.86M | -4.6M | -3.82M | -936K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M | -7.16M |
| Depreciation & Amortization | 4.98M | 4.04M | 1.15M | 901K | 1.77M | 462K | 651K | 447K | 63K | 13K |
| Stock-Based Compensation | 7.42M | 5.51M | 3.17M | 3.14M | 4.22M | 3.38M | 2.58M | 1.89M | 1.85M | 2.64M |
| Deferred Taxes | -12.89M | 0 | 0 | 0 | 0 | -546K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 5.61M | 6.43M | 1.18M | 184K | 189K | 148K | 1.39M | 16K | 2.58M | 1.29M |
| Working Capital Changes | -16.63M | -859K | -698K | 3.53M | 7.66M | -6.21M | 1.01M | -2.06M | 99K | 623K |
| Change in Receivables | -13.41M | -6.4M | -3.12M | -1.56M | 3.62M | -5.42M | 425K | -473K | 0 | 0 |
| Change in Inventory | 2.8M | -5.88M | -1.31M | -354K | -7K | 692K | -862K | -380K | 0 | 0 |
| Change in Payables | 2.24M | 6.81M | 2.32M | 53K | -8K | -570K | 1.77M | -377K | 413K | 539K |
| Cash from Investing | -18.36M | -333K | -40.01M | -775K | -2.79M | -2.56M | -50K | -1.85M | -236K | -130K |
| Capital Expenditures | -15.13M | -333K | -26K | -775K | -38K | -3.26M | -50K | -1.1M | -236K | -130K |
| CapEx % of Revenue | 10.73% | 0.42% | 0.07% | 2.45% | 0.18% | 14.93% | 128.21% | 114.29% | - | - |
| Acquisitions | 0 | 0 | -30M | 0 | 0 | 700K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -3.23M | 0 | -9.99M | 0 | -2.75M | 0 | 0 | -750K | 0 | 0 |
| Cash from Financing | -1.49M | 815K | 32.59M | -957K | -134K | 391K | 31.63M | 5.2M | 21.96M | 18M |
| Debt Issued (Net) | -8M | 0 | 24.15M | -1.16M | -385K | -150K | 2.48M | 4.75M | 0 | 0 |
| Equity Issued (Net) | 6.51M | 598K | 8.19M | 0 | 0 | 541K | 28.78M | 0 | 22.8M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.05M | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 217K | 248K | 198K | 251K | 0 | 367K | 453K | 205K | 18M |
| Net Change in Cash | 18.51M | 11.01M | -6.45M | 5.08M | 1.9M | -6.89M | 9.23M | -14.67M | 13.58M | 13.16M |
| Free Cash Flow | 38.22M | 10.19M | 943K | 6.04M | 2.03M | -7.98M | -22.4M | -19.87M | -8.38M | -4.85M |
| FCF Margin % | 27.09% | 12.75% | 2.42% | 19.09% | 9.57% | -36.55% | -57425.64% | -2072.16% | - | - |
| FCF Growth % | 81.87% | 980.7% | -84.39% | 197.1% | 125.48% | 64.37% | -12.7% | -137.11% | -72.88% | - |
| FCF per Share | 1.15 | 0.38 | 0.04 | 0.24 | 0.08 | -0.32 | -1.07 | -1.12 | -1.31 | -0.28 |
| FCF Conversion (FCF/Net Income) | 0.77x | -2.29x | -0.25x | -7.28x | -0.53x | 2.41x | 0.80x | 0.98x | 0.64x | 0.66x |
| Interest Paid | 3.33M | 0 | 665K | 842K | 730K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 107K | 0 | 82K | 247K | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc. (ETON) generated $10.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Eton Pharmaceuticals, Inc. (ETON) generated $10.2M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Eton Pharmaceuticals, Inc. (ETON) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Volatile quarterly cash conversion
Metrics are mathematically derived from official filings.
Earnings Quality Lags Cash Generation
According to reported quarterly figures, ETON's operating cash flow swung from negative $11.6M in 2025Q4 to positive $35.2M in 2026Q3, with the cash-to-net-income ratio fluctuating sharply rather than tracking earnings steadily.
The operating cash flow to net income ratio ranges from roughly 0.6 to over 4.7 across recent quarters, which suggests that reported earnings are not translating into cash in a consistent manner. The 2026Q3 ratio of 1.00 is largely a function of a $35.2M operating cash inflow matching net income, but the preceding quarters show large working capital swings that appear to drive the timing gap. Investors should monitor whether conversion normalizes once the current quarter's working capital effects reverse, as the current cash picture may not be representative of recurring operations.
Free Cash Flow Turns Sharply Positive
As reported in financial statements, ETON's free cash flow reached $35.2M in 2026Q3 on a 60.8% margin, a marked improvement from the negative $11.6M recorded in 2025Q4.
Capex has been minimal relative to revenue in most recent quarters, so free cash flow closely tracks operating cash flow, making working capital the dominant driver of the trajectory. The 2026Q1 capex/revenue spike of 62.1% appears to be an isolated investment outlay rather than a recurring pattern. The sustainability of the 60.8% FCF margin warrants caution, since it likely reflects a favorable working capital release instead of structurally higher cash earnings.
Working Capital Drives Cash Volatility
Based on EDBL's reported figures, working capital changes swung from a $17.4M outflow in 2025Q4 to a $10.3M inflow in 2025Q3, indicating that receivables, inventory, and payables timing dominates quarterly cash results.
The magnitude of quarterly working capital movements relative to net income suggests that collection timing and wholesaler inventory stocking may be creating substantial noise in reported cash flow. Large swings of this size imply that a meaningful share of quarterly operating cash flow may reverse in subsequent periods. Analysts should examine receivables aging and inventory levels to determine whether recent inflows reflect genuine collections or temporary balance sheet movements.
Cumulative Cash Lags Reported Profits
Across the ten reported quarters, cumulative operating cash flow appears modestly ahead of cumulative net income, though the result depends heavily on the timing of the most recent quarter's inflow.
Summing the disclosed quarters suggests operating cash flow has broadly tracked net income over the period, but the path is uneven and dominated by a few large swings. The pattern indicates that the company's earnings history is not yet a reliable proxy for cash generation. Investors should treat the recent positive cash result as encouraging but not yet proof of durable cash earnings power.
Cash Strength May Be Temporary
The recent cash inflows may reflect working capital release and launch timing rather than recurring cash earnings, and the -5.8% TTM net margin and -18.2% ROE caution against extrapolating current results.
The strongest bear case is that the 2026Q3 operating cash inflow of $35.2M is a one-time working capital reversal following the $17.4M outflow in the prior quarter, not a new run rate. Trailing profitability remains negative, which suggests the business has not yet demonstrated that revenue growth converts to sustained cash earnings. Investors should monitor whether operating cash flow stays positive across several quarters before concluding the cash profile has structurally improved.